Table 2. Detection of CBCs in melanoma patients with PAFC in vivo.
For P1 to P15: CBCs per milliliter in vivo versus in vitro, Spearman correlation = +0.024 (P = 0.93); CBC patient result in vivo versus in vitro, concordance = 12 of 15 (80%) and Cohen’s κ ± SE = −0.10 ± 057. For P19 to P28: CTCs per milliliter in vivo versus in vitro, Spearman correlation = +0.450 (P = 0.1921); CTC patient result in vivo versus in vitro, concordance = 10 of 10 (100%).
| CBCs |
In vivo PAFC |
|||
|---|---|---|---|---|
| Subject no. | Blood volume* |
Number detected |
CBCs per millilite† |
Patient result‡ |
| P1 | 234 | 1 | 0.004 ± 0.004 | Yes |
| P2 | 117 | 0 | 0.000 ± 0.000 | No |
| P3 | 842 | 0 | 0.000 ± 0.000 | No |
| P4 | 690 | 9 | 0.013 ± 0.004 | Yes |
| P5 | 150 | 0 | 0.000 ± 0.000 | No |
| P6 | 501 | 1 | 0.008 ± 0.002 | Yes |
| P7 | 667 | 0 | 0.000 ± 0.000 | No |
| P8 | 954 | 1 | 0.001 ± 0.001 | No |
| P9 | 658 | 0 | 0.000 ± 0.000 | No |
| P10 | 509 | 0 | 0.000 ± 0.000 | No |
| P11 | 164 | 0 | 0.000 ± 0.000 | No |
| P12 | 200 | 0 | 0.000 ± 0.000 | No |
| P13 | 660 | 0 | 0.000 ± 0.000 | No |
| P14 | 516 | 0 | 0.000 ± 0.000 | No |
| P15 | 221 | 0 | 0.000 ± 0.000 | No |
| P16 | 230 | 9 | 0.039 ± 0.013 | Yes |
| P17 | 682 | 0 | 0.000 ± 0.000 | No |
| P18 | 235 | 0 | 0.000 ± 0.000 | No |
| P19 | 242 | 0 | 0.000 ± 0.000 | No |
| P20 | 91 | 0 | 0.000 ± 0.000 | No |
| P21 | 197 | 0 | 0.000 ± 0.000 | No |
| P22 | 295 | 0 | 0.000 ± 0.000 | No |
| P23 | 174 | 0 | 0.000 ± 0.000 | No |
| P24 | 301 | 0 | 0.000 ± 0.000 | No |
| P25 | 33 | 0 | 0.000 ± 0.000 | No |
| P26 | 163 | 0 | 0.000 ± 0.000 | No |
| P27 | 266 | 0 | 0.000 ± 0.000 | No |
| P28 | 80 | 0 | 0.000 ± 0.000 | No |
*
Blood volume is in milliliters.
†
Point estimate ± SE of the estimate.
‡
Patient result was calculated as “yes” if the patient’s CBC rate {in CBCs per milliliter) was elevated above the false-positive CBC rate by >2 SEs of the difference. False-positive CBC rates ± SEs were 0.000 ± 0.000 CBCs/ml in vivo and 0.372 ± 0.131 CBCs/ml in vitro.